Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
J Infect Dis
    January 2018
  1. REID M, Ma Y, Scherzer R, Price JC, et al
    Contribution of liver fibrosis and microbial translocation to immune activation in HIV and HCV.
    J Infect Dis. 2018 Jan 3. pii: 4786614. doi: 10.1093.
    >> Share

    December 2017
  2. ANGELIDOU K, Hunt PW, Landay AL, Wilson CC, et al
    Changes in inflammation but not in T cell activation precede non-AIDS-defining events in a case-control study of patients on long-term antiretroviral therapy.
    J Infect Dis. 2017 Dec 22. pii: 4772233. doi: 10.1093.
    >> Share

  3. KOOIJ KW, Vogt L, Reiss P
    Reply to Moso et al.
    J Infect Dis. 2017 Dec 22. pii: 4772651. doi: 10.1093.
    >> Share

  4. MOSO MA, Woolnough E, Langham F, Hoy JF, et al
    Increasing prevalence and risk of chronic kidney disease in HIV-positive individuals: changing demographics over a six-year period.
    J Infect Dis. 2017 Dec 22. pii: 4772637. doi: 10.1093.
    >> Share

  5. TANSEY C, Zhao C, Hopkins A, Ritter JM, et al
    A Non-human Primate Model for Rectally Transmitted Syphilis.
    J Infect Dis. 2017 Dec 22. pii: 4772175. doi: 10.1093.
    >> Share

  6. GIBBS A, Buggert M, Edfeldt G, Ranefall P, et al
    HIV-infected women have high numbers of CD103-CD8+ T cells residing close to the basal membrane of the ectocervical epithelium.
    J Infect Dis. 2017 Dec 20. pii: 4767924. doi: 10.1093.
    >> Share

  7. SHIELS MS, Kirk GD, Drummond MB, Dhillon D, et al
    HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D.
    J Infect Dis. 2017 Dec 19. pii: 4762465. doi: 10.1093.
    >> Share

  8. WALLENDER E, Vucicevic K, Jagannathan P, Huang L, et al
    Predicting optimal dihydroartemisinin-piperaquine regimens to prevent malaria during pregnancy for HIV-infected women receiving efavirenz.
    J Infect Dis. 2017 Dec 19. pii: 4762345. doi: 10.1093.
    >> Share

  9. GALLANT J, Hsue PY, Shreay S, Meyer N, et al
    Comorbidities Among US Patients With Prevalent HIV Infection-A Trend Analysis.
    J Infect Dis. 2017;216:1525-1533.
    >> Share

  10. VAN DER VALK M, Reiss P
    Noncommunicable Diseases in People Living With HIV: Time for Integrated Care.
    J Infect Dis. 2017;216:1481-1483.
    >> Share

  11. BOPPANA SB, Britt WJ, Fowler K, Hutto SC, et al
    Pathogenesis of Non-Zika Congenital Viral Infections.
    J Infect Dis. 2017;216.
    >> Share

  12. GREGORY CJ, Oduyebo T, Brault AC, Brooks JT, et al
    Modes of Transmission of Zika Virus.
    J Infect Dis. 2017;216.
    >> Share

  13. SIEDNER MJ, Hunt PW
    All About the Albumin? Prognostic Capacity of Serum Albumin in Patients With Treated HIV Infection.
    J Infect Dis. 2017 Dec 13. pii: 4736315. doi: 10.1093.
    >> Share

  14. RONIT A, Sharma S, Baker JV, Mngqibisa R, et al
    Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study.
    J Infect Dis. 2017 Dec 13. pii: 4736314. doi: 10.1093.
    >> Share

  15. KING CC, Ellington SR, Davis NL, Coombs RW, et al
    Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy.
    J Infect Dis. 2017 Dec 12. pii: 4733301. doi: 10.1093.
    >> Share

  16. HAYASHI K, Dong H, Kerr T, Dobrer S, et al
    Declining Mortality Rates in HIV-Infected People Who Inject Drugs During a Seek-and-Treat Initiative in Vancouver, Canada, 1996-2014: A Prospective Cohort Study.
    J Infect Dis. 2017 Dec 12. pii: 4731720. doi: 10.1093.
    >> Share

  17. SIVRO A, McKinnon LR
    Mucosal HIV Shedding During ART.
    J Infect Dis. 2017 Dec 12. pii: 4733302. doi: 10.1093.
    >> Share

  18. RANGANATH N, Sandstrom TS, Burke Schinkel SC, Cote SC, et al
    The oncolytic virus, MG1, targets and eliminates latently HIV-1-infected cells: implications for an HIV cure.
    J Infect Dis. 2017 Dec 8. pii: 4706282. doi: 10.1093.
    >> Share

  19. AJAYKUMAR A, Soudeyns H, Kakkar F, Brophy J, et al
    Leukocyte telomere length at birth and during the early life of HIV-exposed uninfected children following in utero exposure to antiretrovirals.
    J Infect Dis. 2017 Dec 8. pii: 4706016. doi: 10.1093.
    >> Share

  20. NYITRAY AG, Fujimoto K, Zhao J, Giuliano AR, et al
    Prevalence of and risk factors for anal HPV among a sample of predominantly black men who have sex with men in Houston, Texas.
    J Infect Dis. 2017 Dec 5. pii: 4690591. doi: 10.1093.
    >> Share

  21. PATEL P, Bush T, Kojic EM, Conley L, et al
    Prevalence, incidence, and clearance of anal high-risk human papillomavirus (HPV) infection among HIV-infected men in the SUN Study.
    J Infect Dis. 2017 Dec 4. pii: 4689803. doi: 10.1093.
    >> Share

  22. STELLA-ASCARIZ N, Arribas JR, Paredes R, Li JZ, et al
    The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.
    J Infect Dis. 2017;216.
    >> Share

  23. WALLIS CL, Godfrey C, Fitzgibbon JE, Mellors JW, et al
    Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.
    J Infect Dis. 2017;216.
    >> Share

  24. RAIZES E, Hader S, Birx D
    Expansion of Viral Load Testing and the Potential Impact on HIV Drug Resistance.
    J Infect Dis. 2017;216.
    >> Share

    November 2017
  25. MAKVANDI-NEJAD S, Laurenson-Schafer H, Wang L, Wellington D, et al
    Lack of Truncated IFITM3 Transcripts in Cells Homozygous for the rs12252-C Variant That is Associated With Severe Influenza Infection.
    J Infect Dis. 2017 Nov 30. pii: 4676001. doi: 10.1093.
    >> Share

  26. ANDREI G, Gillemot S, Topalis D, Snoeck R, et al
    The anti-HIV drug tenofovir, a reverse transcriptase inhibitor, also targets the herpes simplex virus (HSV) DNA polymerase.
    J Infect Dis. 2017 Nov 23. pii: 4653578. doi: 10.1093.
    >> Share

  27. BOON D, Redd AD, Layendecker O, Engle R, et al
    Hepatitis E virus seroprevalence and correlates of anti-HEV IgG antibodies in the Rakai District, Uganda.
    J Infect Dis. 2017 Nov 23. pii: 4653785. doi: 10.1093.
    >> Share

  28. JUSTICE AC, Erlandson KM, Miotti PG, Landay A, et al
    Can Biomarkers Advance HIV Research and Care in the ART Era?
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    >> Share

  29. CHAUDHURY CS, Sheehan J, Chairez C, Akoth E, et al
    No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.
    J Infect Dis. 2017 Nov 17. doi: 10.1093.
    >> Share

  30. BUTI M, Riveiro-Barciela M, Esteban R
    Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection.
    J Infect Dis. 2017;216.
    >> Share

  31. YEN YF, Lan YC, Huang CT, Jen IA, et al
    Human Immunodeficiency Virus Infection Increases the Risk of Incident Autoimmune Hemolytic Anemia: A Population-Based Cohort Study in Taiwan.
    J Infect Dis. 2017;216:1000-1007.
    >> Share

  32. HUANG YA, Tao G, Samandari T, Hoover KW, et al
    Laboratory Testing of a Cohort of Commercially Insured Users of HIV Preexposure Prophylaxis in the United States, 2011-2015.
    J Infect Dis. 2017 Nov 14. doi: 10.1093.
    >> Share

  33. STEBA GS, Koekkoek SM, Vanhommerig JW, Brinkman K, et al
    DC-SIGN Polymorphisms Associated with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users.
    J Infect Dis. 2017 Nov 13. doi: 10.1093.
    >> Share

  34. REID MJA, Goosby E
    Patient-Centered Tuberculosis Programs Are Necessary to End the Epidemic.
    J Infect Dis. 2017;216.
    >> Share

  35. NAIDOO P, Theron G, Rangaka MX, Chihota VN, et al
    The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges.
    J Infect Dis. 2017;216.
    >> Share

  36. CHURCHYARD G, Kim P, Shah NS, Rustomjee R, et al
    What We Know About Tuberculosis Transmission: An Overview.
    J Infect Dis. 2017;216.
    >> Share

  37. MATHEMA B, Andrews JR, Cohen T, Borgdorff MW, et al
    Drivers of Tuberculosis Transmission.
    J Infect Dis. 2017;216.
    >> Share

  38. AULD SC, Kasmar AG, Dowdy DW, Mathema B, et al
    Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?
    J Infect Dis. 2017;216.
    >> Share

  39. SHAH NS, Kim P, Kana BD, Rustomjee R, et al
    Getting to Zero New Tuberculosis Infections: Insights From the National Institutes of Health/US Centers for Disease Control and Prevention/Bill & Melinda Gates Foundation Workshop on Research Needs for Halting Tuberculosis Transmission.
    J Infect Dis. 2017;216.
    >> Share

  40. NEWTON R, Labo N, Wakeham K, Miley W, et al
    Kaposi's sarcoma associated herpesvirus in a rural Ugandan cohort: 1992-2008.
    J Infect Dis. 2017 Nov 1. doi: 10.1093.
    >> Share

    October 2017
  41. VAN ZOEST RA, Underwood J, De Francesco D, Sabin CA, et al
    Structural brain abnormalities in successfully treated HIV infection: associations with disease and cerebrospinal fluid biomarkers.
    J Infect Dis. 2017 Oct 24. doi: 10.1093.
    >> Share

  42. SIBERRY GK, Amzel A, Ramos A, Rivadeneira ED, et al
    Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries.
    J Infect Dis. 2017 Oct 17. doi: 10.1093.
    >> Share

  43. KIRKEGAARD-KLITBO DM, Langkilde A, Mejer N, Andersen O, et al
    Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection.
    J Infect Dis. 2017;216:819-823.
    >> Share

  44. LI G, Nunoya JI, Cheng L, Reszka-Blanco N, et al
    Regulatory T Cells Contribute to HIV-1 Reservoir Persistence in CD4 T Cells Through cAMP-Dependent Mechanisms in Humanized Mice In Vivo.
    J Infect Dis. 2017 Oct 14. doi: 10.1093.
    >> Share

  45. BERTAGNOLIO S, Beanland RL, Jordan MR, Doherty M, et al
    The World Health Organization's Response to Emerging Human Immunodeficiency Virus Drug Resistance and a Call for Global Action.
    J Infect Dis. 2017 Oct 13. doi: 10.1093.
    >> Share

  46. DUARTE HA, Panpradist N, Beck IA, Lutz B, et al
    Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Oct 13. doi: 10.1093.
    >> Share

  47. PINTYE J, Baeten JM, Celum C, Mugo N, et al
    Maternal tenofovir disoproxil fumarate use during pregnancy is not associated with adverse perinatal outcomes among HIV-infected East African women: a prospective study.
    J Infect Dis. 2017 Oct 10. doi: 10.1093.
    >> Share

  48. SILVERMAN RA, Beck IA, Kiptinness C, Levine M, et al
    Prevalence of Pre-antiretroviral Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-infected Individuals Initiating Therapy in Kenya, 2013-2014.
    J Infect Dis. 2017 Oct 10. doi: 10.1093.
    >> Share

  49. NGOBENI R, Samie A, Moonah S, Watanabe K, et al
    Entamoeba Species in South Africa: Correlations With the Host Microbiome, Parasite Burdens, and First Description of Entamoeba bangladeshi Outside of Asia.
    J Infect Dis. 2017 Oct 8. pii: 4372272. doi: 10.1093.
    >> Share

  50. ROH ME, Shiboski S, Natureeba P, Kakuru A, et al
    Protective effect of indoor residual spraying of insecticide on preterm birth among pregnant women with HIV in Uganda: A secondary data analysis.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    >> Share

  51. MINIOR T, Douglas M, Edgil D, Srivastava M, et al
    The Critical Role of Supply Chains in Preventing Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Settings.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    >> Share

  52. ZHUKOVA A, Cutino-Moguel T, Gascuel O, Pillay D, et al
    The Role of Phylogenetics as a Tool to Predict the Spread of Resistance.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    >> Share

  53. SINGH D, Dhummakupt A, Siems L, Persaud D, et al
    Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    >> Share

  54. PARASKEVIS D
    Investigation of Human Immunodeficiency Virus Outbreaks Among People Who Inject Drugs: Timely Diagnosis and Molecular Surveillance are Crucial.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    >> Share

  55. CHUN HM, Obeng-Aduasare YF, Broyles LN, Ellenberger D, et al
    Expansion of Viral Load Testing and the Potential Impact on Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    >> Share

  56. BUNJUN R, Riou C, Soares AP, Thawer N, et al
    Effect of HIV on the frequency and number of Mycobacterium tuberculosis-specific CD4+ T cells in blood and the airways in latent tuberculosis infection.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    >> Share

  57. CAMPBELL EM, Jia H, Shankar A, Hanson D, et al
    Detailed Transmission Network Analysis of a Large Opiate-Driven Outbreak of HIV Infection in the United States.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    >> Share

  58. DONAHUE CARLSON R, Sheth AN, Read TD, Frisch MB, et al
    The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    >> Share

    September 2017
  59. BORRE ED, Hyle EP, Paltiel AD, Neilan AM, et al
    The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States.
    J Infect Dis. 2017 Sep 28. doi: 10.1093.
    >> Share

  60. ADIMORA AA
    Implementing National HIV/AIDS Strategy 2015 Treatment Targets Is Cost-effective and Would Save Lives: What Other Evidence Do We Need?
    J Infect Dis. 2017 Sep 28. doi: 10.1093.
    >> Share

  61. PRENDERGAST AJ, Chasekwa B, Rukobo S, Govha M, et al
    Intestinal Damage and Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Zimbabwean Infants.
    J Infect Dis. 2017;216:651-661.
    >> Share

  62. FOLDI J, Kozhaya L, McCarty B, Mwamzuka M, et al
    HIV-Infected Children Have Elevated Levels of PD-1+ Memory CD4 T Cells With Low Proliferative Capacity and High Inflammatory Cytokine Effector Functions.
    J Infect Dis. 2017;216:641-650.
    >> Share

  63. ROCKWOOD N, Sirgel F, Streicher E, Warren R, et al
    Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence.
    J Infect Dis. 2017;216:632-640.
    >> Share

  64. KOOIJ KW, Vogt L, Wit FWNM, van der Valk M, et al
    Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls.
    J Infect Dis. 2017;216:622-631.
    >> Share

  65. MOORE T, Dembry LM, Saag MS
    Sunday in the Park with Infectious Disease: Workforce Mismatch in a Colorful Universe of Possibilities.
    J Infect Dis. 2017;216.
    >> Share

  66. GALLANT JE
    Human Immunodeficiency Virus Medicine.
    J Infect Dis. 2017;216.
    >> Share

  67. PIROFSKI LA
    Life as an Infectious Diseases Physician Scientist: Science is Humanity's Lifeline.
    J Infect Dis. 2017;216.
    >> Share

  68. DEL RIO C
    From Trained Infectious Diseases Clinician to Global Health Leader, Reflections on the Last 30 Years.
    J Infect Dis. 2017;216.
    >> Share

  69. NOGUERA-JULIAN M, Edgil D, Harrigan PR, Sandstrom P, et al
    Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance.
    J Infect Dis. 2017 Sep 15. doi: 10.1093.
    >> Share

  70. GODFREY C, Bobkova M, Boucher C, Ravasi G, et al
    Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Sep 14. doi: 10.1093.
    >> Share

  71. CHIKATA T, Murakoshi H, Koyanagi M, Honda K, et al
    Control of HIV-1 by an HLA-B*52:01-C*12:02 protective haplotype.
    J Infect Dis. 2017 Sep 14. doi: 10.1093.
    >> Share

  72. MCLAREN PJ, Pulit SL, Gurdasani D, Bartha I, et al
    Evaluating the impact of functional genetic variation on HIV-1 control.
    J Infect Dis. 2017 Sep 9. doi: 10.1093.
    >> Share

  73. LIU Y, Gaisa MM, Wang X, Swartz TH, et al
    Immune Microenvironments of Anal Cancer Precursors Differ by HIV-serostatus, Affecting Ablation Outcomes.
    J Infect Dis. 2017 Sep 2. doi: 10.1093.
    >> Share

  74. NING T, Wolfe A, Nie J, Huang W, et al
    Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization.
    J Infect Dis. 2017 Sep 2. doi: 10.1093.
    >> Share

  75. AKE JA, Schuetz A, Pegu P, Wieczorek L, et al
    Safety and Immunogenicity of PENNVAX(R)-G DNA Prime Administered by Biojector(R) 2000 or CELLECTRA(R) Electroporation Device with Modified Vaccinia Ankara-CMDR Boost.
    J Infect Dis. 2017 Sep 2. doi: 10.1093.
    >> Share

  76. SMITH B
    Toward Understanding the When and Why of Human Immunodeficiency Virus-Associated Stroke.
    J Infect Dis. 2017;216:509-510.
    >> Share

  77. BENJAMIN LA, Allain TJ, Mzinganjira H, Connor MD, et al
    The Role of Human Immunodeficiency Virus-Associated Vasculopathy in the Etiology of Stroke.
    J Infect Dis. 2017;216:545-553.
    >> Share

  78. MOLLAN KR, Tierney C, Hellwege JN, Eron JJ, et al
    Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.
    J Infect Dis. 2017;216:554-564.
    >> Share

    August 2017
  79. WEITZMANN MN, Vikulina T, Roser-Page S, Yamaguchi M, et al
    Homeostatic Expansion of CD4+ T-cells Promotes Cortical and Trabecular Bone Loss while CD8+ T-cells Induce Trabecular Bone Loss Only.
    J Infect Dis. 2017 Aug 25. doi: 10.1093.
    >> Share

  80. ASMUTH DM, Thompson CG, Chun TW, Ma ZM, et al
    Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal GALT Immune Reconstitution in HIV-infected Patients Initiating Antiretroviral Therapy.
    J Infect Dis. 2017 Aug 23. doi: 10.1093.
    >> Share

  81. BOEIJEN LL, Montanari NR, de Groen RA, van Oord GW, et al
    Mucosal-associated invariant T (MAIT) cells are more activated in chronic hepatitis B, but not depleted in blood: reversal by antiviral therapy.
    J Infect Dis. 2017 Aug 23. doi: 10.1093.
    >> Share

  82. DE POKOMANDY A, Kaufman E, de Castro C, Mayrand MH, et al
    The EVVA Cohort Study: Anal and Cervical Type-Specific Human Papillomavirus Prevalence, Persistence, and Cytologic Findings in Women Living With HIV.
    J Infect Dis. 2017;216:447-456.
    >> Share

  83. CRABTREE KL, Wojcicki JM, Minhas V, Kankasa C, et al
    Food and Drink Sharing in the Household are Associated with HHV-8 Seroconversion in a Cohort of Zambian Children.
    J Infect Dis. 2017 Aug 14. doi: 10.1093.
    >> Share

  84. CLUTTER DS, Zhou S, Varghese V, Rhee SY, et al
    Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing.
    J Infect Dis. 2017;216:387-391.
    >> Share

  85. VAN LAARHOVEN A, Dian S, Ganiem AR, van Crevel R, et al
    Reply to Neeradi et al and Dhawan and Sankhyan.
    J Infect Dis. 2017;216:395-396.
    >> Share

    July 2017
  86. HENRICH TJ, Hobbs KS, Hanhauser E, Scully E, et al
    Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy.
    J Infect Dis. 2017;216:254-262.
    >> Share

  87. MARTIN DH, Manhart LE, Workowski KA
    Mycoplasma genitalium From Basic Science to Public Health: Summary of the Results From a National Institute of Allergy and Infectious Disesases Technical Consultation and Consensus Recommendations for Future Research Priorities.
    J Infect Dis. 2017;216.
    >> Share

  88. HORNER PJ, Martin DH
    Mycoplasma genitalium Infection in Men.
    J Infect Dis. 2017;216.
    >> Share

    June 2017
  89. DELAUGERRE C, Antoni G, Mahjoub N, Pialoux G, et al
    Assessment of HIV Screening Tests for Pre-Exposure Prophylaxis Programs.
    J Infect Dis. 2017 Jun 27. doi: 10.1093.
    >> Share

  90. SCHOEMAN JC, Moutloatse GP, Harms AC, Vreeken RJ, et al
    Fetal metabolic stress disrupts immune homeostasis and induces pro-inflammatory responses in HIV-1 and cART-exposed infants.
    J Infect Dis. 2017 Jun 17. doi: 10.1093.
    >> Share

  91. GODFREY C, Thigpen MC, Crawford KW, Jean-Phillippe P, et al
    Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.
    J Infect Dis. 2017 Jun 17. doi: 10.1093.
    >> Share

  92. KOPP JB
    Chronic Kidney Disease in the Aging Human Immunodeficiency Virus-Infected Population.
    J Infect Dis. 2017 Jun 13. doi: 10.1093.
    >> Share

    May 2017
  93. HIRAKAWA H, Gatanaga H, Ochi H, Fukuda T, et al
    Antiretroviral therapy containing HIV protease inhibitors enhances fracture risk by impairing osteoblast differentiation and bone quality.
    J Infect Dis. 2017 May 19. doi: 10.1093.
    >> Share

  94. STEINAU M, Gorbach P, Gratzer B, Braxton J, et al
    Concordance between Anal and Oral Human Papillomavirus (HPV) Infections Among Young Men Who Have Sex with Men.
    J Infect Dis. 2017 May 15. doi: 10.1093.
    >> Share

  95. KEATING SM, Pilcher CD, Jain V, Lebedeva M, et al
    HIV Antibodies Detect HIV Persistence and Low Level Viral Replication.
    J Infect Dis. 2017 May 11. doi: 10.1093.
    >> Share

  96. LUO Z, Li Z, Martin L, Wan Z, et al
    Pathological role of anti-CD4 antibodies in HIV-infected immunologic non-responders under viral suppressive antiretroviral therapy.
    J Infect Dis. 2017 May 11. doi: 10.1093.
    >> Share

    April 2017
  97. GAY CL, Bosch RJ, Ritz J, Hataye JM, et al
    Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.
    J Infect Dis. 2017 Apr 18. doi: 10.1093.
    >> Share

  98. THUONG NTT, Heemskerk D, Tram TTB, Thao LTP, et al
    Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral Inflammation and Survival From Tuberculous Meningitis.
    J Infect Dis. 2017 Apr 17. doi: 10.1093.
    >> Share

  99. VAN LAARHOVEN A, Dian S, Ruesen C, Hayati E, et al
    Clinical Parameters, Routine Inflammatory Markers, and LTA4H Genotype as Predictors of Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia.
    J Infect Dis. 2017 Apr 17. doi: 10.1093.
    >> Share

  100. CHOI JY, Pond SLK, Anderson CM, Richman DD, et al
    Molecular Features of the V1-V4 Coding Region of Sexually Transmitted HIV-1.
    J Infect Dis. 2017 Apr 17. doi: 10.1093.
    >> Share

  101. SYPSA V, Psichogiou M, Paraskevis D, Nikolopoulos G, et al
    Rapid Decline in HIV Incidence Among Persons Who Inject Drugs During a Fast-Track Combination Prevention Program After an HIV Outbreak in Athens.
    J Infect Dis. 2017 Apr 12. doi: 10.1093.
    >> Share

  102. CHAN PA, Flanigan TP
    Effective HIV Prevention Interventions and the Need for Rapid Mobilization to Address HIV Outbreaks Among At-Risk Populations.
    J Infect Dis. 2017 Apr 12. doi: 10.1093.
    >> Share

  103. HERRERA BB, Chang CA, Hamel DJ, Mboup S, et al
    Continued transmission of Zika virus in humans in West Africa, 1992-2016.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    >> Share

    March 2017
  104. VERMUND SH
    The Continuum of HIV Care in the Urban United States: Black Men Who Have Sex With Men (MSM) Are Less Likely Than White MSM to Receive Antiretroviral Therapy.
    J Infect Dis. 2017 Mar 29. doi: 10.1093.
    >> Share

  105. RAHIMY E, Li FY, Hagberg L, Fuchs D, et al
    Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy.
    J Infect Dis. 2017 Mar 29. doi: 10.1093.
    >> Share

  106. HOOTS BE, Finlayson TJ, Wejnert C, Paz-Bailey G, et al
    Updated Data on Linkage to Human Immunodeficiency Virus Care and Antiretroviral Treatment Among Men Who Have Sex With Men-20 Cities, United States.
    J Infect Dis. 2017 Mar 29. doi: 10.1093.
    >> Share

  107. DING Y, Lin H, Liu X, Wong FY, et al
    Higher Prevalence of Frailty Among a Sample of HIV-Infected Middle-aged and Older Chinese Adults Is Associated With Neurocognitive Impairment and Depressive Symptoms.
    J Infect Dis. 2017 Mar 16. doi: 10.1093.
    >> Share

  108. ERLANDSON KM, Wu K, Koletar SL, Kalayjian RC, et al
    Association Between Frailty and Components of the Frailty Phenotype With Modifiable Risk Factors and Antiretroviral Therapy.
    J Infect Dis. 2017;215:933-937.
    >> Share

  109. KHOURY G, Fromentin R, Solomon A, Hartogensis W, et al
    Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy.
    J Infect Dis. 2017;215:911-919.
    >> Share

  110. UPRETY P, Lindsey JC, Levin MJ, Rainwater-Lovett K, et al
    Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1-Infected African Infants and Rotavirus Vaccine Responses.
    J Infect Dis. 2017;215:928-932.
    >> Share

  111. MARGOT NA, Wong P, Kulkarni R, White K, et al
    Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
    J Infect Dis. 2017;215:920-927.
    >> Share

  112. CELUM C, Hong T, Cent A, Donnell D, et al
    Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study.
    J Infect Dis. 2017;215:907-910.
    >> Share

  113. BORITZ EA, Douek DC
    Perspectives on Human Immunodeficiency Virus (HIV) Cure: HIV Persistence in Tissue.
    J Infect Dis. 2017;215.
    >> Share

  114. RILEY JL, Montaner LJ
    Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.
    J Infect Dis. 2017;215.
    >> Share

  115. HENRICH TJ, Deeks SG, Pillai SK
    Measuring the Size of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies.
    J Infect Dis. 2017;215.
    >> Share

  116. NIXON CC, Mavigner M, Silvestri G, Garcia JV, et al
    In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies.
    J Infect Dis. 2017;215.
    >> Share

  117. MULLINS JI, Frenkel LM
    Clonal Expansion of Human Immunodeficiency Virus-Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy.
    J Infect Dis. 2017;215.
    >> Share

  118. MARGOLIS DM
    Towards an HIV Cure: a View of a Developing Field.
    J Infect Dis. 2017;215.
    >> Share

  119. MARGOLIS DM, Archin NM
    Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.
    J Infect Dis. 2017;215.
    >> Share

  120. FERRARI G, Pollara J, Tomaras GD, Haynes BF, et al
    Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection.
    J Infect Dis. 2017;215.
    >> Share

  121. WYLES D, Saag M, Viani RM, Lalezari J, et al
    TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
    J Infect Dis. 2017 Mar 14. doi: 10.1093.
    >> Share

  122. LEE S, Byakwaga H, Boum Y, Burdo TH, et al
    Immunologic Pathways that Predict Mortality in HIV-Infected Ugandans Initiating ART.
    J Infect Dis. 2017 Mar 1. doi: 10.1093.
    >> Share

    February 2017
  123. TER KUILE FO, Taylor SM
    Gilding the lily?: Enhancing antenatal malaria prevention in HIV-infected women.
    J Infect Dis. 2017 Feb 28. doi: 10.1093.
    >> Share

  124. NATUREEBA P, Kakuru A, Muhindo M, Littmann E, et al
    Intermittent Preventive Treatment with Dihydroartemisinin-piperaquine for the Prevention of Malaria among HIV-infected Pregnant Women.
    J Infect Dis. 2017 Feb 22. doi: 10.1093.
    >> Share

  125. PHILLIPS AN, Stover J, Cambiano V, Nakagawa F, et al
    Impact of HIV drug resistance on HIV/AIDS associated mortality, new infections and antiretroviral therapy program costs in sub-Saharan Africa.
    J Infect Dis. 2017 Feb 17. doi: 10.1093.
    >> Share

  126. LEVIS W
    Clofazimine mechanisms of action in Mycobacteria, HIV, and Cancer.
    J Infect Dis. 2017 Feb 12. doi: 10.1093.
    >> Share

  127. HANNA DB, Lin J, Post WS, Hodis HN, et al
    Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men.
    J Infect Dis. 2017 Feb 12. doi: 10.1093.
    >> Share

  128. JANES HE, Cohen KW, Frahm N, De Rosa SC, et al
    Higher T cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial.
    J Infect Dis. 2017 Feb 12. doi: 10.1093.
    >> Share

  129. FEINSTEIN MJ, Lloyd-Jones DM
    Macrophage inflammation and cardiovascular disease in HIV: Mechanistic Insights and Future Directions.
    J Infect Dis. 2017 Feb 12. doi: 10.1093.
    >> Share

  130. DZANIBE S, Adrian PV, Mlacha SZ, Dangor Z, et al
    Reduced Transplacental Transfer of Group B Streptococcus Surface Protein Antibodies in HIV-infected Mother-Newborn Dyads.
    J Infect Dis. 2017 Feb 9. doi: 10.1093.
    >> Share

  131. KHOURY G, Fromentin R, Solomon A, Hartogensis W, et al
    HIV persistence and T-cell activation in blood, rectal and lymph node tissue in HIV-infected individuals receiving suppressive ART.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    >> Share

  132. GARGANO JW, Unger ER, Liu G, Steinau M, et al
    Prevalence of Genital Human Papillomavirus in Males, United States, 2013-2014.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    >> Share

  133. UPRETY P, Lindsey JC, Levin MJ, Rainwater-Lovett K, et al
    Inflammation and Immune Activation in Antiretroviral-Treated HIV-1-Infected African Infants and Rotavirus Vaccine Responses.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    >> Share

    January 2017
  134. MARGOT NA, Wong P, Kulkarni R, White K, et al
    Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse Transcriptase and Protease in Antiretroviral Treatment-Naive Patients do not Affect Response to Tenofovir Disoproxil Fumarate- or Tenofovir Alafenamide-Containing Regimens.
    J Infect Dis. 2017 Jan 30. doi: 10.1093.
    >> Share

  135. CELUM C, Hong T, Cent A, Donnell D, et al
    HSV-2 acquisition among HIV-1 infected adults treated with tenofovir as part of combination antiretroviral therapy: Results from the ACTG A5175 PEARLS study.
    J Infect Dis. 2017 Jan 30. doi: 10.1093.
    >> Share

  136. LOFGREN S, Hullsiek KH, Morawski BM, Nabeta HW, et al
    Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis.
    J Infect Dis. 2017 Jan 30. doi: 10.1093.
    >> Share

  137. LIN WW, Nelson A, Ryon JJ, Moss WJ, et al
    Plasma cytokines and chemokines in Zambian children with measles: innate responses and association with HIV-1 co-infection and in-hospital mortality.
    J Infect Dis. 2017 Jan 24. pii: jix012. doi: 10.1093.
    >> Share

  138. ZANNI MV, Toribio M, Wilks MQ, Lu MT, et al
    Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV.
    J Infect Dis. 2017 Jan 16. doi: 10.1093.
    >> Share

  139. JANSSEN S, Schutz C, Ward AM, Huson MA, et al
    Hemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis: A Prospective Cohort Study.
    J Infect Dis. 2017;215:247-258.
    >> Share

  140. HOBBS CV, Anderson C, Neal J, Sahu T, et al
    Trimethoprim-Sulfamethoxazole Prophylaxis During Live Malaria Sporozoite Immunization Induces Long-Lived, Homologous, and Heterologous Protective Immunity Against Sporozoite Challenge.
    J Infect Dis. 2017;215:122-130.
    >> Share

  141. NYOMBAYIRE J, Anzala O, Gazzard B, Karita E, et al
    First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    J Infect Dis. 2017;215:95-104.
    >> Share

  142. OTTICHILO RK, Polyak CS, Guyah B, Singa B, et al
    Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis.
    J Infect Dis. 2017;215:88-94.
    >> Share

    December 2016
  143. CHENG A, Chang SY, Sun HY, Tsai MS, et al
    Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy.
    J Infect Dis. 2016 Dec 23. pii: jiw605. doi: 10.1093.
    >> Share

  144. GRABOWSKI MK, Gravitt PE, Gray RH, Serwadda D, et al
    Trends and determinants of human papillomavirus concordance among HIV-positive and HIV-negative heterosexual couples in Rakai, Uganda.
    J Infect Dis. 2016 Dec 23. pii: jiw631. doi: 10.1093.
    >> Share

  145. EVANS C, Chasekwa B, Rukobo S, Govha M, et al
    CMV acquisition and inflammation in HIV-exposed uninfected Zimbabwean infants.
    J Infect Dis. 2016 Dec 23. pii: jiw630. doi: 10.1093.
    >> Share

  146. BIRSE KD, Romas LM, Guthrie BL, Nilsson P, et al
    Genital injury signatures and microbiome alterations associated with depot medroxyprogesterone acetate usage and intravaginal drying practices.
    J Infect Dis. 2016 Dec 23. pii: jiw590. doi: 10.1093.
    >> Share

  147. BALKUS JE, Srinivasan S, Anzala O, Kimani J, et al
    Impact of periodic presumptive treatment for bacterial vaginosis on the vaginal microbiome among women participating in the Preventing Vaginal Infections trial.
    J Infect Dis. 2016 Dec 22. pii: jiw622. doi: 10.1093.
    >> Share

  148. MESQUITA PM, Preston-Hurlburt P, Keller MJ, Vudattu N, et al
    Role of IL-32 in HIV Reactivation and its Link to HIV-HSV Coinfection.
    J Infect Dis. 2016 Dec 22. pii: jiw612. doi: 10.1093.
    >> Share

  149. BIALAS KM, Westreich D, Cisneros de la Rosa E, Nelson CS, et al
    Maternal Antibody Responses and Nonprimary Congenital Cytomegalovirus Infection of HIV-1-Exposed Infants.
    J Infect Dis. 2016;214:1916-1923.
    >> Share

  150. STEEGEN K, Bronze M, Papathanasopoulos MA, van Zyl G, et al
    Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa.
    J Infect Dis. 2016;214:1826-1830.
    >> Share

  151. MARAIS S, Lai RP, Wilkinson KA, Meintjes G, et al
    Inflammasome activation underlies central nervous system deterioration in HIV-associated tuberculosis.
    J Infect Dis. 2016.
    >> Share

  152. MCFARLAND EJ, Powell TM, Onyango-Makumbi C, Zhang W, et al
    Ontogeny of CD4+ T Lymphocytes with Phenotypic Susceptibility to HIV-1 during Exclusive and Non-Exclusive Breastfeeding in HIV-1-exposed Ugandan Infants.
    J Infect Dis. 2016.
    >> Share

  153. DZANIBE S, Adrian PV, Kimaro Mlacha SZ, Dangor Z, et al
    Reduced trans-placental transfer of group B Streptococcus surface protein antibodies in HIV-infected mother-newborn dyads.
    J Infect Dis. 2016.
    >> Share

  154. TSO FY, Sawyer A, Kwon EH, Mudenda V, et al
    Kaposi's sarcoma-associated herpesvirus infection of neurons in HIV positive patients.
    J Infect Dis. 2016.
    >> Share

  155. BRAUNSTEIN SL, Robertson MM, Myers J, Abraham B, et al
    Increase in CD4+ T-Cell Count at the Time of HIV Diagnosis and Antiretroviral Treatment Initiation Among Persons With HIV in New York City.
    J Infect Dis. 2016;214:1682-1686.
    >> Share

    November 2016
  156. ALTHOFF KN
    The Shifting Paradigm of Care for Adults Living With HIV: Smoking Cessation for Longer Life.
    J Infect Dis. 2016.
    >> Share

  157. REDDY KP, Parker RA, Losina E, Baggett TP, et al
    Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study.
    J Infect Dis. 2016.
    >> Share

  158. GULICK RM, Wilkin TJ, Chen YQ, Landovitz RJ, et al
    PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305).
    J Infect Dis. 2016.
    >> Share

  159. GUNTHARD HF, Scherrer AU
    HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug Resistance.
    J Infect Dis. 2016;214:1289-1291.
    >> Share

    October 2016
  160. ERLANDSON KM, Ng D, Jacobson LP, Margolick JB, et al
    Inflammation, Immune Activation, Immunosenescence, and Hormonal Biomarkers in the Frailty-Related Phenotype of Men with or at Risk for HIV.
    J Infect Dis. 2016.
    >> Share

  161. IMP BM, Rubin LH, Tien PC, Plankey MW, et al
    Monocyte Activation is Associated with Worse Cognitive Performance in Virologically Suppressed HIV-Infected Women.
    J Infect Dis. 2016.
    >> Share

  162. ANDERSON AM, Munoz-Moreno JA, McClernon D, Ellis RJ, et al
    Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
    J Infect Dis. 2016.
    >> Share

  163. MUDD JC, Panigrahi S, Kyi B, Moon SH, et al
    Inflammatory function of CX3CR1+ CD8 T cells in treated HIV infection is modulated by platelet interactions.
    J Infect Dis. 2016.
    >> Share

  164. ECKARD AR, Meissner EG, Singh I, McComsey GA, et al
    Cardiovascular Disease, Statins, and HIV.
    J Infect Dis. 2016;214 Suppl 2:S83-92.
    >> Share

  165. KOETHE JR, Heimburger DC, PrayGod G, Filteau S, et al
    From Wasting to Obesity: The Contribution of Nutritional Status to Immune Activation in HIV Infection.
    J Infect Dis. 2016;214 Suppl 2:S75-82.
    >> Share

  166. GIANELLA S, Letendre S
    Cytomegalovirus and HIV: A Dangerous Pas de Deux.
    J Infect Dis. 2016;214 Suppl 2:S67-74.
    >> Share

  167. MUDD JC, Brenchley JM
    Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression.
    J Infect Dis. 2016;214 Suppl 2:S58-66.
    >> Share

  168. FREEMAN ML, Shive CL, Nguyen TP, Younes SA, et al
    Cytokines and T-Cell Homeostasis in HIV Infection.
    J Infect Dis. 2016;214 Suppl 2:S51-7.
    >> Share

  169. HUNT PW, Lee SA, Siedner MJ
    Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection.
    J Infect Dis. 2016;214 Suppl 2:S44-50.
    >> Share

  170. SIEG SF
    Persistent Inflammation in Treated HIV Disease.
    J Infect Dis. 2016;214 Suppl 2:S43.
    >> Share

    September 2016
  171. KOOIJ KW, Wit FW, Booiman T, van der Valk M, et al
    Cigarette smoking and inflammation, monocyte activation and coagulation in HIV-infected individuals on antiretroviral therapy compared to uninfected individuals.
    J Infect Dis. 2016.
    >> Share

  172. EDEN A, Nilsson S, Hagberg L, Fuchs D, et al
    Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: a Longitudinal Study.
    J Infect Dis. 2016.
    >> Share

  173. WANG L, Wiener J, Bulterys M, Wei X, et al
    Hepatitis B Viral Load Response to two Antiviral Regimens (Tenofovir/Lamivudine vs Lamivudine) in HIV and HBV Co-Infected Pregnant Women in Guangxi, China: the Tenofovir in Pregnancy (TiP) Study.
    J Infect Dis. 2016.
    >> Share

  174. BUCHACZ K, Lau B, Jing Y, Bosch R, et al
    Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010.
    J Infect Dis. 2016;214:862-72.
    >> Share

  175. FURRER H
    Opportunistic Diseases During HIV Infection-Things Aren't What They Used to Be, or Are They?
    J Infect Dis. 2016;214:830-1.
    >> Share

  176. PETERSON I, Bar-Zeev N, Kennedy N, Ho A, et al
    Respiratory virus-associated severe acute respiratory illness (SARI) and viral clustering in Malawian children in a setting with a high prevalence of HIV, malaria and malnutrition.
    J Infect Dis. 2016.
    >> Share

  177. POPESCU I, Drummond MB, Gama L, Lambert A, et al
    HIV Suppression Restores Lung Mucosal CD4+ T-Cell Viral Immunity and Resolves CD8+ Alveolitis in Patients at Risk for HIV-associated COPD.
    J Infect Dis. 2016.
    >> Share

    August 2016
  178. IMAZ A, Martinez-Picado J, Niubo J, Kashuba AD, et al
    HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Initiating a First Antiretroviral Regimen.
    J Infect Dis. 2016.
    >> Share

  179. COOMBS RW, Krieger JN
    Semen Remains the Way Forward to understand HIV-1 Transmission.
    J Infect Dis. 2016.
    >> Share

  180. RODRIGO C, Eltahla AA, Bull RA, Grebely J, et al
    Historical trends in the hepatitis C virus epidemics in North America and Australia.
    J Infect Dis. 2016.
    >> Share

  181. GUTIERREZ J, Menshawy K, Goldman J, Dwork AJ, et al
    Metalloproteinases and brain arterial remodeling with and without HIV.
    J Infect Dis. 2016.
    >> Share

  182. SRINIVASA S, Burdo TH, Williams KC, Mitten EK, et al
    Effects of Sodium Restriction on Activation of the Renin-Angiotensin-Aldosterone System and Immune Indices in HIV.
    J Infect Dis. 2016.
    >> Share

  183. KOSTADINOVA L, Shive C, Judge C, Zebrowski E, et al
    During HCV and HCV-HIV infection elevated plasma Autotaxin is associated with LPA and markers of immune activation that normalize during IFN-free HCV therapy.
    J Infect Dis. 2016.
    >> Share

  184. MOFENSON LM
    Early Infant HIV Diagnosis: How Early is Early Enough?
    J Infect Dis. 2016.
    >> Share

  185. FRANCKE JA, Penazzato M, Hou T, Abrams EJ, et al
    Clinical impact and cost-effectiveness of early infant HIV diagnosis in South Africa: Test timing and frequency.
    J Infect Dis. 2016.
    >> Share

  186. WALTER ND, de Jong BC, Garcia BJ, Dolganov GM, et al
    Adaptation of M. tuberculosis to impaired host immunity in HIV-infected patients.
    J Infect Dis. 2016.
    >> Share

  187. REIMERS LL, Mehta SD, Massad LS, Burk RD, et al
    The Cervicovaginal Microbiota and Its Associations with Human Papillomavirus (HPV) Detection in HIV-Infected and HIV-Uninfected Women.
    J Infect Dis. 2016.
    >> Share

  188. MARKOWITZ M, Deren S, Cleland C, La Mar M, et al
    Chronic hepatitis C infection and the pro-inflammatory effects of injection drug use.
    J Infect Dis. 2016.
    >> Share

  189. KILIANSKI A, Nuzzo JB, Modjarrad K
    Reply to Lipsitch.
    J Infect Dis. 2016.
    >> Share

  190. GONZALEZ OA, Sagar M
    Antibodies and acidic environment do not enhance HIV-1 transcytosis.
    J Infect Dis. 2016.
    >> Share

  191. RYOM L, Lundgren JD, Ross M, Kirk O, et al
    Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study.
    J Infect Dis. 2016.
    >> Share

  192. FIERER DS
    The Order of Addition of Immunocompromise: The Effects of HIV Infection on Fibrosis Progression of Hepatitis C-infected Patients.
    J Infect Dis. 2016.
    >> Share

    July 2016
  193. MASSUD I, Mitchell J, Babusis D, Deyounks F, et al
    Chemoprophylaxis with oral emtricitabine and tenofovir alafenamide combination protects macaques from rectal SHIV infection.
    J Infect Dis. 2016.
    >> Share

  194. WALL KM, Kilembe W, Vwalika B, Ravindhran P, et al
    Hormonal contraceptive use among HIV-positive women and HIV transmission risk to male partners, Zambia, 1994-2012.
    J Infect Dis. 2016.
    >> Share

  195. DIEDRICH CR, O'Hern J, Gutierrez MG, Allie N, et al
    Relationship between HIV-1 co-infection, IL-10, and M. tuberculosis in human lymph node granulomas.
    J Infect Dis. 2016.
    >> Share

  196. CANADAY DH, Toossi Z
    Granulomatous responses in HIV/TB co-infection.
    J Infect Dis. 2016.
    >> Share

  197. BAETEN JM
    Making an Impact With Preexposure Prophylaxis for Prevention of HIV Infection.
    J Infect Dis. 2016.
    >> Share

  198. JENNESS SM, Goodreau SM, Rosenberg E, Beylerian EN, et al
    Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States.
    J Infect Dis. 2016.
    >> Share

  199. BOENDER TS, Hamers RL, Ondoa P, Wellington M, et al
    Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.
    J Infect Dis. 2016.
    >> Share

    June 2016
  200. DERUAZ M, Moldt B, Le KM, Power KA, et al
    Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo.
    J Infect Dis. 2016.
    >> Share

  201. HUNT PW
    sCD163 and Clinical Outcomes in Treated HIV: Insights into Mechanisms.
    J Infect Dis. 2016.
    >> Share

  202. KELESIDIS T, Moser C, Stein JH, Brown TT, et al
    Changes in markers of T cell senescence and exhaustion with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
    J Infect Dis. 2016.
    >> Share

  203. KNUDSEN TB, Ertner G, Petersen J, Moller HJ, et al
    Plasma CD163 independently predicts all-cause mortality from HIV-1 infection.
    J Infect Dis. 2016.
    >> Share

  204. GRANT PM, Kitch D, McComsey GA, Collier AC, et al
    Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.
    J Infect Dis. 2016.
    >> Share

  205. MEITES E, Gorbach PM, Gratzer B, Panicker G, et al
    Monitoring for HPV Vaccine Impact among Gay, Bisexual and other Men who have Sex with Men - United States, 2012-2014.
    J Infect Dis. 2016.
    >> Share

  206. CHEN YI MEI SL, Burchell J, Skinner N, Millen R, et al
    Toll-like receptor expression and signalling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis C infection.
    J Infect Dis. 2016.
    >> Share

    May 2016
  207. LAPRISE JF, Markowitz LE, Chesson HW, Drolet M, et al
    COMPARING 2- AND 3-DOSE 9-VALENT HPV VACCINE SCHEDULES IN THE U.S.: A COST-EFFECTIVENESS ANALYSIS.
    J Infect Dis. 2016.
    >> Share

  208. WHITE E, Smit E, Churchill D, Collins S, et al
    No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.
    J Infect Dis. 2016.
    >> Share

  209. SHILAIH M, Marzel A, Scherrer AU, Braun DL, et al
    Dually Active HIV/HBV Antiretrovirals Protect Against Incident Hepatitis B Infections: Potential for Prophylaxis.
    J Infect Dis. 2016.
    >> Share

  210. PRENDERGAST AJ, Szubert AJ, Berejena C, Pimundu G, et al
    Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy.
    J Infect Dis. 2016.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016